Tizaro 7.5mg Tirzepatide Injection for Diabetes Management and Weight Loss Support

Actually went with the 7.5mg pre-filled syringes because that's the sweet spot for most patients ramping up — the 2.5mg starter dose is too low for sustained effect, and we usually have stock of this strength, but confirm lead time for the 5mg or 10mg depending on your batch.

The CAS and molecular weight aren't on my radar right now, but the HPLC purity we're seeing is consistently above 99% with teh COA from the last three batches we checked, and that's tighter tolerance than most generic GLP-1 agonists we've sourced for the US market where FDA compliance is non-negotiable for import docs anyway.

What it does is bind to both GIP and GLP-1 receptors, which is why the weight loss support is actually better than semaglutide for this class, though it's not suited for patients with a history of MTC or MEN2 — those contraindications are standerd across GLP-1s, so we're flagging that on the TDS for the UK buyers who need the SDS to clear customs, usually within 20 days or so.

One thing you wouldn't think to ask: the plunger rod on these prefilled syringes has a slightly different resistnce than the ones we got last quarter, so if your team is doing subcutaneous injections in a clinical setting, they'll notice the feel — not a dealbreaker, just something we caught in last batch.

Side effects are pretty much what you'd expect: nausea and diarrhea hit about 15-20% of users initially, but the decreased appetite is actually a plus for weight loss patients, though we're not spinning that as a benefit for type 2 diabetes management where the primary indication is glycemic control.